503675331 02/02/2016 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3721967

SUBMISSION TYPE:		NEW ASSIGNMENT	NEW ASSIGNMENT				
NATURE OF CONVEYANCE:		ASSIGNMENT	ASSIGNMENT				
CONVEYING PARTY DA	ATA						
		Name	Execution Date				
JOSEPH M. FAYAD M.D).		08/15/2013				
RECEIVING PARTY DA	ТА						
Name:	THERAB	THERABRAKE, INC.					
Street Address:	100 CROSBY BOULEVARD						
City:	EGGERTSVILLE						
State/Country:	NEW YO	NEW YORK					
Postal Code:	14226						
	•						
PROPERTY NUMBERS	Total: 1						
Property Type		Number					
Application Number:	14	4677044					
	(2 e sent to t	215)656-2498 the e-mail address first; if that is unified in the state of the state					
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i>	(2 e sent to t provided;	,					
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email:	2) e sent to t provided; 2 [.] pt	t he e-mail address first; if that is u if that is unsuccessful, it will be s 15-656-3381 to.phil@dlapiper.com					
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name:	(2 e sent to t provided; 2 ⁻ pt IF	the e-mail address first; if that is unif that is unif that is unsuccessful, it will be s 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US)					
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1:	(2 e sent to t provided; 2 [:] pt IF O	the e-mail address first; if that is unif that is unsuccessful, it will be s 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) NE LIBERTY PLACE	ent via US Mail.				
Fax Number: <i>Correspondence will be using a fax number, if µ</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2:	(2 e sent to t provided; 2 pt IF 0 16	the e-mail address first; if that is unif that is unif that is unsuccessful, it will be s 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US)	ent via US Mail.				
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unif that is unsuccessful, it will be so 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) NE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19	ent via US Mail.				
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unit if that is unit if that is unsuccessful, it will be set to that is unsuccessful, it will be set to phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) NE LIBERTY PLACE 650 MARKET STREET, SUITE 4900	ent via US Mail.				
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4:	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unit if that is unsuccessful, it will be set to phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) NE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001)	ent via US Mail.				
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 4: ATTORNEY DOCKET NUMATE OF SUBMITTER: BIGNATURE:	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unit if that is unsuccessful, it will be set 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) ONE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001) PAUL CARANGO	ent via US Mail.				
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2:	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unit if that is unsuccessful, it will be set 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) ONE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001) PAUL CARANGO /Paul Carango/	ent via US Mail.				
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: TTORNEY DOCKET NU IAME OF SUBMITTER: DATE SIGNED: Total Attachments: 4	(2 e sent to t provided; 2 pt IF 0 16 P	the e-mail address first; if that is unit if that is unsuccessful, it will be set 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) ONE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001) PAUL CARANGO /Paul Carango/	ent via US Mail.				
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET NUME NAME OF SUBMITTER: DATE SIGNED: Total Attachments: 4 source=Assignment#page	(2 e sent to t provided; 2 pt IF 0 16 2 10 2 10 2 10 2 10 2 10 2 10 2 10	the e-mail address first; if that is unit if that is unsuccessful, it will be set 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) ONE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001) PAUL CARANGO /Paul Carango/	ent via US Mail.				
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 2: Address Line 2: Address Line 4: ATTORNEY DOCKET NUNAME OF SUBMITTER: SIGNATURE: DATE SIGNED:	(2 e sent to t provided; 2 pt IF 0 16 2 10 2 10 2 10 2 10 2 10 2 10 2 10	the e-mail address first; if that is unit if that is unsuccessful, it will be set 15-656-3381 to.phil@dlapiper.com P GROUP OF DLA PIPER LLP (US) ONE LIBERTY PLACE 650 MARKET STREET, SUITE 4900 HILADELPHIA, PENNSYLVANIA 19 PAC-1-B (379364-000001) PAUL CARANGO /Paul Carango/	ent via US Mail.				

ASSIGNMENT OF PATENT APPLICATIONS AND INTELLECTUAL PROPERTY RIGHTS

This agreement, dated as of the date appearing in the jurat below, is by and between Joseph M. Fayad, M.D., an individual, residing at 3583 Tobias Lane, Henderson, NV 89120 ("Fayad") and TheraBrake, Inc., a Delaware corporation, residing at 100 Crosby Boulevard, Eggertsville, NY 14226 ("TheraBrake").

WHEREAS, Fayad has invented certain new and useful improvements in the art of inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease, states and conditions (the "Controlled Release Dosage Invention");

WHEREAS, Fayad has filed for patent protection covering the Controlled Release Dosage Invention, including International Patent Application No. PCT/US09/05016 and U.S. Patent Application No. 12/932,633 published as U.S. Pub. No. 2011/0268795 (the "Patent Applications");

WHEREAS, Fayad intends to file continuation applications or new patent applications as needed to cover his ongoing discoveries in connection with the Controlled Release Dosage Invention;

WHEREAS, Fayad lacks the time, inclination, experience and resources to exploit the Controlled Release Dosage Invention to its fullest potential;

PATENT

REEL: 037641 FRAME: 0994

WHEREAS, Fayad and another individual, Jerome Schentag, formed TheraBrake to exploit the Controlled Release Dosage Invention to its fullest potential;

WHEREAS, Fayad wishes to assign all of his right, title and interest in the Controlled Release Dosage Invention to TheraBrake;

WHEREAS, TheraBrake wishes to accept the assignment of all of Fayad's right, title and interest in the Controlled Release Dosage Invention;

NOW, THEREFORE, for good and valuable consideration, Fayad, by these presents, does sell, assign and transfer unto TheraBrake the full and exclusive right to the Controlled Release Dosage Invention in the United States, and the entire rights, title and interest in and to any and all patents which may be granted therefor in the United States, including pursuant to the Patent Applications, which are expressly assigned by Fayad to TheraBrake hereunder. Fayad hereby authorizes and requests the Director of the U.S. Patent & Trademark Office to issue any patent pursuant to the Controlled Release Dosage Invention and the Patent Applications, and to transfer any provisional or non-provisional patent applications for same, to TheraBrake, including the entire right, title and interest in and to the same, for its sole use and behoof, and for the use and behoof of its successors and assigns, to the full end of the term for which any such patent may be granted, as fully and entirely as the same would have been held by Fayad had this assignment and sale not been made. This assignment expressly covers all continuation applications and new patent applications filed by Fayad in connection with the Controlled Release Dosage

Page 2 of 4

PATENT REEL: 037641 FRAME: 0995 Invention and the Patent Applications, at any time in the future. A copy of this assignment agreement shall suffice to support the assignment to TheraBrake of any such continuation applications at the time they are filed with the United States Patent & Trademark Office. Notwithstanding, Fayad hereby agrees to execute such documents as shall be reasonably necessary to support the efforts of TheraBrake to file patent applications based on the Patent Applications or on the Controlled Release Dosage Invention generally with the U.S. Patent & Trademark Office, and all continuation patent applications connected with same.

Fayad does further sell, assign and transfer unto TheraBrake the full and exclusive right to the Controlled Release Dosage Invention throughout the world, including pursuant to the Patent Applications, and the entire rights, title and interest in and to any and all patents which may be granted therefor anywhere in the world, as based on the PCT system or any other treaty rights flowing from the Patent Applications or otherwise. Fayad hereby agrees to execute such documents as shall be reasonably necessary to support the efforts of TheraBrake to file foreign country patent applications based on the Patent Applications or on the Controlled Release Dosage Invention generally, and all continuation patent applications connected with same. Fayad further agrees that the entire right, title and interest in and to such foreign country patents that issue from such foreign country patent applications shall be in the name of TheraBrake, and for its sole use and behoof, and for the use and behoof of its successors and assigns, to the full end of the term for which such patents may be granted, as fully and entirely as the same would have been held by Fayad had this assignment and sale not been made.

Page 3 of 4

PATENT REEL: 037641 FRAME: 0996

J	OSEPH M.	FAYAD, M.D.	r	, Ther	RABRAKE, INC.	
7021	ph 1	W/16	4 <i>01</i> —	and	Sunt	
State of N	evada					
County of	Clark) ss:)				
	Defeue		woowod Josowh	M Forred N	1 David a alma	

Before me personally appeared Joseph M. Fayad, M.D. and acknowledged Mine the foregoing instrument to be his free act and deed this 15th day of July, 2013. MARCELINO B. CAPITO, JR Notary Public-State of Nevada APPT. NO. 10-1241-1 My App. Expires December 29, 2013 Notary Public

PATENT REEL: 037641 FRAME: 0997

Page 4 of 4

RECORDED: 02/02/2016